Researchers at Memorial Sloan Kettering Cancer Center are utilizing mRNA technology, previously used to combat COVID-19, to develop a novel approach to fight pancreatic cancer. They are creating personalized mRNA vaccines that enhance the immune system's ability to recognize and eradicate an individual's unique cancer cells. This phase 2 clinical trial could significantly alter global cancer treatment methods and survival rates. The vaccines use specific tumor proteins, known as neoantigens, to enable a targeted immune response against cancer cells. Personalized medicine involves genetically sequencing the tumor after surgery to develop the vaccine, which then prompts dendritic cells to produce these proteins and instruct the immune system to combat identical neoantigen-bearing tumor cells. This could substantially diminish the likelihood of cancer recurrence.
Full article here: https://lawsuithelpdesk.com/title-unleashing-the-power-of-mrna-the-revolutionary-fight-against-pancreatic-cancer/
